Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.

Amanam I, Gupta R, Mambetsariev I, Salgia R. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.

View in: PubMed

collapse authors with profiles